| scholarly article | Q13442814 |
| P2093 | author name string | M. N. Pollak | |
| P2860 | cites work | The blooming of the French lilac | Q22241897 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 778-90 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | Investigating metformin for cancer prevention and treatment: the end of the beginning | |
| P478 | volume | 2 |
| Q98564727 | A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo |
| Q59807299 | A Multi-Mode Bioactive Agent Isolated From L. Fill. With Therapeutic Potential for Type 2 Diabetes Mellitus |
| Q52682466 | A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. |
| Q37170305 | A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. |
| Q26774351 | A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis |
| Q89282213 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors |
| Q59337418 | A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study |
| Q47240106 | A reappraisal on metformin |
| Q38796334 | A review for clinicians: Prostate cancer and the antineoplastic properties of metformin |
| Q39124486 | A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. |
| Q61809287 | Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2 |
| Q51740938 | Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1α-induced pro-angiogenic factor. |
| Q48311315 | Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats |
| Q28485299 | Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin |
| Q59150041 | Analyses of Biguanides and Related Compounds in Biological and Environmental Samples by HPLC |
| Q47284172 | Androgen receptor overexpression in prostate cancer in type 2 diabetes |
| Q53177190 | Anti-Diabetic Drugs: Cure or Risk Factors for Cancer? |
| Q35196533 | Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer |
| Q38250719 | Antihyperglycaemic therapies and cancer risk |
| Q49906268 | Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells |
| Q89896564 | Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3 |
| Q35084900 | Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. |
| Q35909683 | Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? |
| Q37206477 | Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study |
| Q35898773 | Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy |
| Q33587154 | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. |
| Q33829461 | CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity |
| Q34258945 | Calorie restriction and cancer prevention: a mechanistic perspective |
| Q26738550 | Cancer Clocks Out for Lunch: Disruption of Circadian Rhythm and Metabolic Oscillation in Cancer |
| Q42245590 | Cancer metabolism as a therapeutic target: finding the right target(s) in the context of tumor heterogeneity, evolution, and metabolic plasticity |
| Q28079306 | Cancer metabolism at a glance |
| Q30242051 | Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? |
| Q38336993 | Catabolic metabolism during cancer EMT. |
| Q37092913 | Cellular fatty acid metabolism and cancer |
| Q27026428 | Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer |
| Q36194518 | Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia |
| Q64058265 | Combination of metformin and paclitaxel suppresses proliferation and induces apoptosis of human prostate cancer cells via oxidative stress and targeting the mitochondria-dependent pathway |
| Q38818730 | Combinational strategies of metformin and chemotherapy in cancers |
| Q36926148 | Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions |
| Q38390595 | Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: implications for prognosis and clinical outcome |
| Q47945526 | Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis |
| Q91658562 | Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) |
| Q36056076 | Diabetes and Hepatitis C: A Two-Way Association |
| Q92669981 | Diabetes and its Potential Impact on Head and Neck Oncogenesis |
| Q40037417 | Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime. |
| Q37299288 | Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin |
| Q34334262 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. |
| Q60054020 | Disease or not, aging is easily treatable |
| Q47948290 | Drug repurposing for the treatment of glioblastoma multiforme. |
| Q37732297 | Drugs that modulate aging: the promising yet difficult path ahead |
| Q26784630 | Dysregulated metabolism contributes to oncogenesis |
| Q47636038 | E3 ubiquitin ligases in cancer and implications for therapies |
| Q90654893 | Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial |
| Q37326781 | Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line |
| Q49623717 | Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo |
| Q38715697 | Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line. |
| Q36587643 | Effects of limiting energy availability via diet and physical activity on mammalian target of rapamycin-related signaling in rat mammary carcinomas |
| Q42848863 | Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria |
| Q41548205 | Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis |
| Q92378892 | Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [18F]HX4 PET imaging study in colorectal cancer xenografts |
| Q58694444 | Effects of metformin treatment on radiotherapy efficacy in patients with cancer and diabetes: a systematic review and meta-analysis |
| Q34468454 | Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat. |
| Q36394649 | EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer |
| Q37747513 | Emerging roles of lipid metabolism in cancer metastasis |
| Q41822613 | Enhanced Response of Metformin towards the Cancer Cells due to Synergism with Multi-walled Carbon Nanotubes in Photothermal Therapy |
| Q28391921 | Epithelial cancers in the post-genomic era: should we reconsider our lifestyle? |
| Q92524624 | FDG uptake tracks the oxidative damage in diabetic skeletal muscle: An experimental study |
| Q34684420 | Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes |
| Q33829205 | From rapalogs to anti-aging formula |
| Q39028862 | Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism |
| Q37521408 | Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer |
| Q37525828 | Glucose promotes breast cancer aggression and reduces metformin efficacy. |
| Q38835936 | Glucose-deprivation increases thyroid cancer cells sensitivity to metformin |
| Q27005955 | Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies |
| Q36665063 | High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum |
| Q34075636 | Hyperglycemia promotes K-Ras-induced lung tumorigenesis through BASCs amplification |
| Q36414231 | Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer |
| Q91826221 | Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin |
| Q99724917 | Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing |
| Q40554709 | Impact of metformin on the progression of MGUS to multiple myeloma |
| Q49194546 | Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice |
| Q34008143 | Increased oxidative metabolism in the Li-Fraumeni syndrome |
| Q36410079 | Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients |
| Q36905125 | Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin |
| Q40499822 | K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria |
| Q36292001 | Koschei the immortal and anti-aging drugs |
| Q36630561 | LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin |
| Q41619824 | Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer |
| Q35163721 | Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models |
| Q38289532 | Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics |
| Q28555000 | MATE2 Expression Is Associated with Cancer Cell Response to Metformin |
| Q54109544 | Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. |
| Q88720563 | Metabolic changes in bladder cancer |
| Q47101870 | Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties |
| Q37462711 | Metabolic roles of AMPK and metformin in cancer cells |
| Q28551227 | Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis |
| Q42093002 | Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells. |
| Q91774964 | Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells |
| Q36261224 | Metformin Is Associated with a Favorable Outcome in Diabetic Patients with Cervical Lymph Node Metastasis of Differentiated Thyroid Cancer |
| Q36418806 | Metformin Promotes Apoptosis but Suppresses Autophagy in Glucose-Deprived H4IIE Hepatocellular Carcinoma Cells |
| Q39225251 | Metformin Reduces Lipogenesis Markers in Obese Mice Fed a Low-Carbohydrate and High-Fat Diet |
| Q28552408 | Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts |
| Q47165414 | Metformin affects thyroid function in male rats |
| Q33890763 | Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer |
| Q38819039 | Metformin and Prostate Cancer: a New Role for an Old Drug. |
| Q41136911 | Metformin and cancer: Technical and clinical implications for FDG-PET imaging |
| Q37030873 | Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk |
| Q33971668 | Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells |
| Q38555403 | Metformin and prostate cancer stem cells: a novel therapeutic target |
| Q42561182 | Metformin and the incidence of cancer in patients with diabetes: a nested case-control study |
| Q40250983 | Metformin and the incidence of viral associated cancers in patients with type 2 diabetes. |
| Q43607131 | Metformin and the risk of endometrial cancer: a population-based cohort study |
| Q26822045 | Metformin and thyroid: an update |
| Q92733028 | Metformin as Potential Therapy for High-Grade Glioma |
| Q28538155 | Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug |
| Q36005565 | Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways |
| Q36356287 | Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2 |
| Q39149779 | Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. |
| Q41897802 | Metformin directly acts on mitochondria to alter cellular bioenergetics. |
| Q30665188 | Metformin effects on biochemical recurrence and metabolic signaling in the prostate |
| Q47985167 | Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P-gp-overexpressing MCF-7 cells. |
| Q55262517 | Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. |
| Q40869466 | Metformin for cancer prevention: a reason for optimism |
| Q36901902 | Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population |
| Q34957038 | Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma |
| Q30540902 | Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. |
| Q34360789 | Metformin improves healthspan and lifespan in mice |
| Q38829871 | Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification |
| Q38996447 | Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial |
| Q35600122 | Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response |
| Q37570847 | Metformin inhibits skin tumor promotion in overweight and obese mice |
| Q39177084 | Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation |
| Q35550204 | Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma |
| Q38766321 | Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation |
| Q38973866 | Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines |
| Q35793665 | Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction |
| Q36788544 | Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. |
| Q37620713 | Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling |
| Q37231995 | Metformin use and improved response to therapy in rectal cancer |
| Q36249114 | Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus |
| Q42700700 | Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis |
| Q64973113 | Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. |
| Q43106555 | Metformin, aging and cancer. |
| Q34658712 | Metformin--mode of action and clinical implications for diabetes and cancer |
| Q36863754 | Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence |
| Q37608817 | Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention |
| Q36902966 | Metformin: a case of divide and conquer. |
| Q36214971 | Metformin: a modulator of bevacizumab activity in cancer? A case report |
| Q38584636 | Metformin: risk-benefit profile with a focus on cancer |
| Q37059785 | Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells |
| Q38693299 | Mitochondrial Dynamics and Heart Failure |
| Q92542993 | Mitochondrial Involvement in Migration, Invasion and Metastasis |
| Q37478905 | Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. |
| Q39031270 | Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). |
| Q91965196 | Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer |
| Q89989620 | New drugs are not enough‑drug repositioning in oncology: An update |
| Q39272833 | New insights into antidiabetic drugs: Possible applications in cancer treatment. |
| Q38748916 | No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study |
| Q59150001 | Novel contribution of chromatography in the development and analyses of metformin hydrochloride in biological and environmental samples |
| Q30361298 | Obesity and cancer pathogenesis. |
| Q37200502 | Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients |
| Q36377956 | Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. |
| Q37353982 | Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer |
| Q47817375 | Patient- and Cell Type-Specific Heterogeneity of Metformin Response |
| Q35675277 | Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer Cells |
| Q37318124 | Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma |
| Q59138314 | Pleiotropic Effects of Metformin on Cancer |
| Q33655236 | Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review |
| Q39030844 | Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females |
| Q34567724 | Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling |
| Q37123877 | Potential applications for biguanides in oncology |
| Q38101281 | Prevention and intervention trials for colorectal cancer. |
| Q60309687 | Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes |
| Q42365321 | Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin |
| Q37448089 | Regulation of metformin response by breast cancer associated gene 2. |
| Q38185970 | Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery |
| Q64098059 | Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity |
| Q38695734 | Repurposing metformin for the prevention of cancer and cancer recurrence |
| Q36679911 | Repurposing old drugs to chemoprevention: the case of metformin. |
| Q38637111 | Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly. |
| Q88404555 | Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles |
| Q90311460 | STAT3 and STAT5 Activation in Solid Cancers |
| Q44670997 | Screening Novel Molecular Targets of Metformin in Breast Cancer by Proteomic Approach |
| Q53714665 | Screening and preventive medication. |
| Q35633876 | Selective inhibition of deactivated mitochondrial complex I by biguanides |
| Q47150073 | Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion. |
| Q34548130 | Syrosingopine sensitizes cancer cells to killing by metformin |
| Q59357580 | Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model |
| Q38792334 | Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions |
| Q36545721 | Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. |
| Q36191986 | Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. |
| Q38997351 | Targeting mutant p53 in cancer: a long road to precision therapy. |
| Q37506032 | Targeting the LKB1 tumor suppressor |
| Q38368049 | Targeting the translation machinery in cancer |
| Q37690270 | The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells |
| Q92019026 | The Elusive Link Between Cancer FDG Uptake and Glycolytic Flux Explains the Preserved Diagnostic Accuracy of PET/CT in Diabetes |
| Q38549743 | The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer |
| Q35609517 | The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link |
| Q52552476 | The effects of metformin on gut microbiota and the immune system as research frontiers. |
| Q38728567 | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development |
| Q58705856 | The implications of signaling lipids in cancer metastasis |
| Q36782275 | The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells |
| Q37317381 | The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells |
| Q88869040 | Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes |
| Q64120581 | Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer |
| Q34407535 | Type 2 diabetes as a redox disease |
| Q38699316 | UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis |
| Q35368220 | Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy |
| Q26750845 | Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs |
| Q33721921 | When less may be more: calorie restriction and response to cancer therapy |
| Q26797301 | Why does obesity promote cancer? Epidemiology, biology, and open questions |
| Q91973686 | mTOR as a central regulator of lifespan and aging |
| Q93053344 | mTOR signalling and cellular metabolism are mutual determinants in cancer |
| Q55002919 | p53 and metabolism: from mechanism to therapeutics. |
Search more.